The Blue Jays are loading up. Melky is just the most recent deal after they completed a blockbuster 12-player trade with the Miami Marlins where they acquired Josh Johnson, Jose Reyes, Mark Buehrle, Emilio Bonifacio, and John Buck. They might have been good before, but if Melky can come even close to recreating his pre-PED numbers than he makes the lineup that much deeper and rivaling both the Yankees and the Orioles.
That’s obviously the question everybody is wondering — what can we expect from Melky? He had very strong numbers this season, .346/.390/.516, but just two years ago he was with Atlanta and hit a weak .255/.317/.354. His production will obviously end up being somewhere in between those two starting points and the Jays are now banking that it’ll be closer to his 2012 numbers.
As for Melky, who cost himself quite a bit of money when he tested positive for PEDs, this was a pretty solid deal. Most were probably thinking that he wouldn’t get much more than a one-year deal and maybe an option, but here he’s getting a two-year pact and $16 million isn’t terrible. It gives him a little job security and he’ll still be hitting the market as a 30-year-old afterward so if he reestablishes himself then he could still be in line for another solid pay day.
The Blue Jays are taking a bit of a risk here. It could turn out that his numbers were artificially inflated, but if he is good than that’s takes their lineup from pretty good to one of the best in the league. It’s a gamble, but it could end up being a good one.